Q3 2025 Earnings Call Transcript November 6, 2025 Operator: Good afternoon, and welcome to the ADMA Biologics Third Quarter 2025 Financial Results and Business Update Conference Call on Wednesday, ...

The FDA on Thursday approved daratumumab-hyaluronidase (Darzalex Faspro) as the first drug for high-risk smoldering multiple ...

Results revealed racial inequities in hospitalization and treatment delays among patients with mpox who received tecovirimat.

A randomized trial comparing an intensive to a standard diagnostic approach showed the suspected etiology, in cases of MI with nonobstructive coronary arteries, is often wrong.

Kura Oncology’s consensus analyst price target has nudged upward, rising from $27.00 to $27.18 following new coverage and insight into the company’s outlook. This minor revision signals a cautiously ...

Total revenue for the quarter ended September 30, 2025 was $134.2 million, up 12% from $119.8 million in the same period of 2024. This growth and operational momentum was driven primarily by continued ...

Abalos Therapeutics announced today that it will present new preclinical data on the development of ABX-001 and its potential to further intensify anti-tumoral effects when combined with bispecific ...

Pain is common among patients with IIMs, with moderate to severe levels associated with greater fatigue, worse physical ...

Q3 2025 Earnings Call Transcript November 4, 2025 Kura Oncology, Inc. misses on earnings expectations. Reported EPS is ...

Perimenopause was linked to higher PsA disease activity and greater tender/swollen joint counts when compared with the pre- ...

NUTLEY, N.J., Nov. 3, 2025 /PRNewswire/ -- Eisai announced today the presentation of clinical research in gynecologic oncology during the International Gynecologic Cancer Society (IGCS) 2025 Annual ...